Submitted: 15 Oct 2019
Accepted: 24 Apr 2020
ePublished: 08 May 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Cardiovasc Thorac Res. 2020;12(2): 90-96.
doi: 10.34172/jcvtr.2020.16
PMID: 32626548
PMCID: PMC7321000
  Abstract View: 264
  PDF Download: 163

Original Article

The impact of oral nicorandil pre-treatment on ST resolution and clinical outcome of patients with acute ST-segment elevation myocardial infarction undergoing primary coronary angioplasty: A randomized placebo controlled trial

Behnaz Akbari 1, Samad Ghaffari 1 ORCID logo, Naser Aslanabadi 1, Bahram Sohrabi 1, Leili Pourafkari 1, Fariborz Akbarzadeh 1, Hasan Javadzadegan 1, Ahmad Separham 1* ORCID logo, Malihe Sehati 1

1 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
*Corresponding Author: Ahmad Separham, Email: aseparham@gmail.com


Introduction: Literature has shown the effects of intravenous/intracoronary nicorandil on increased myocardial salvage in patients with ST-segment elevation myocardial infarction (STEMI) treated with mechanical reperfusion. However, the possible cardioprotective effect of oral nicorandil on the clinical outcome prior to primary coronary angioplasty is not well documented. Our aim was to assess the effect of oral nicorandil on primary percutaneous coronary intervention (PPCI).

Methods: A total of 240 patients with acute STEMI undergoing PPCI were randomly assigned to oral nicorandil (Intervention, n=116) and placebo (Control, n=124) groups. The intervention group received 20 mg oral nicorandil at the emergency department and another 20 mg oral nicorandil in the catheterization laboratory just before the procedure. The control group received matched placebo. Our primary outcome was ST-segment resolution ≥50% one hour after primary angioplasty. Secondary outcome was in-hospital major adverse cardiovascular events (MACE), defined as a composite of death, ventricular arrhythmia, heart failure and stroke.

Results: In the patients of intervention and control groups, the occurrence of ST-segment resolution ≥ 50% were 68.1% and 62.9% respectively, (P=0.27). In-hospital MACE occurred less frequently in the intervention group, compared to placebo group (11.2% vs. 22.5%, P=0.012).

Conclusion: Although the administration of oral nicorandil before primary coronary angioplasty did not improve ST-segment resolution in patients with acute STEMI, its promoting effects was remarkable on in-hospital clinical outcomes.
Clinical Registration: IRCT20140512017666N1

Keywords: Acute Myocardial Infarction, Oral Nicorandil, ST-Segment Resolution, Primary Angioplasty, Cardioprotection
First Name
Last Name
Email Address
Security code

Abstract View: 264

Your browser does not support the canvas element.

PDF Download: 163

Your browser does not support the canvas element.